State of New Jersey Common Pension Fund D Raises Holdings in 10x Genomics, Inc. (NASDAQ:TXG)

State of New Jersey Common Pension Fund D lifted its holdings in shares of 10x Genomics, Inc. (NASDAQ:TXG) by 17.8% during the fourth quarter, Holdings Channel.com reports. The fund owned 59,357 shares of the company’s stock after acquiring an additional 8,980 shares during the period. State of New Jersey Common Pension Fund D’s holdings in 10x Genomics were worth $3,322,000 as of its most recent SEC filing.

A number of other large investors have also recently bought and sold shares of TXG. Commonwealth Equity Services LLC boosted its position in 10x Genomics by 26.0% in the third quarter. Commonwealth Equity Services LLC now owns 7,193 shares of the company’s stock valued at $297,000 after buying an additional 1,486 shares during the last quarter. Xponance Inc. boosted its position in 10x Genomics by 3.2% in the third quarter. Xponance Inc. now owns 13,060 shares of the company’s stock valued at $539,000 after buying an additional 400 shares during the last quarter. Bank of New York Mellon Corp boosted its position in 10x Genomics by 13.9% in the third quarter. Bank of New York Mellon Corp now owns 1,010,256 shares of the company’s stock valued at $41,673,000 after buying an additional 122,981 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank boosted its position in 10x Genomics by 13.2% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 20,777 shares of the company’s stock valued at $857,000 after buying an additional 2,419 shares during the last quarter. Finally, Strs Ohio boosted its position in 10x Genomics by 16.8% in the third quarter. Strs Ohio now owns 13,789 shares of the company’s stock valued at $568,000 after buying an additional 1,986 shares during the last quarter. Hedge funds and other institutional investors own 84.68% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on TXG shares. Stifel Nicolaus dropped their target price on 10x Genomics from $68.00 to $63.00 and set a “buy” rating on the stock in a research report on Friday, February 16th. Deutsche Bank Aktiengesellschaft dropped their price objective on shares of 10x Genomics from $60.00 to $55.00 and set a “buy” rating on the stock in a research note on Thursday, April 18th. Finally, Barclays dropped their price objective on shares of 10x Genomics from $55.00 to $45.00 and set an “overweight” rating on the stock in a research note on Wednesday, April 10th. One equities research analyst has rated the stock with a hold rating and eight have given a buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $60.22.

Insider Activity

In other news, CEO Serge Saxonov sold 1,000 shares of 10x Genomics stock in a transaction dated Friday, February 9th. The shares were sold at an average price of $49.53, for a total value of $49,530.00. Following the sale, the chief executive officer now owns 855,381 shares in the company, valued at $42,367,020.93. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In related news, CEO Serge Saxonov sold 1,000 shares of the business’s stock in a transaction dated Friday, February 9th. The shares were sold at an average price of $49.53, for a total transaction of $49,530.00. Following the transaction, the chief executive officer now directly owns 855,381 shares in the company, valued at $42,367,020.93. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Benjamin J. Hindson sold 2,613 shares of the business’s stock in a transaction dated Thursday, February 22nd. The stock was sold at an average price of $46.34, for a total transaction of $121,086.42. Following the transaction, the insider now owns 283,059 shares in the company, valued at $13,116,954.06. The disclosure for this sale can be found here. Insiders have sold a total of 12,959 shares of company stock worth $592,806 over the last 90 days. 10.65% of the stock is currently owned by company insiders.

10x Genomics Stock Performance

TXG opened at $27.59 on Friday. 10x Genomics, Inc. has a fifty-two week low of $26.30 and a fifty-two week high of $63.57. The company has a fifty day moving average of $37.70 and a two-hundred day moving average of $42.52. The stock has a market capitalization of $3.29 billion, a price-to-earnings ratio of -12.71 and a beta of 1.90.

10x Genomics (NASDAQ:TXG) last released its quarterly earnings data on Thursday, February 15th. The company reported ($0.41) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.05). 10x Genomics had a negative net margin of 41.17% and a negative return on equity of 28.82%. The firm had revenue of $183.98 million during the quarter, compared to analysts’ expectations of $182.73 million. During the same period in the previous year, the firm posted ($0.15) EPS. The firm’s quarterly revenue was up 17.8% on a year-over-year basis. On average, equities research analysts forecast that 10x Genomics, Inc. will post -1.47 earnings per share for the current year.

10x Genomics Company Profile

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.